<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00068276</url>
  </required_header>
  <id_info>
    <org_study_id>CCCWFU-29203</org_study_id>
    <secondary_id>CDR0000318802</secondary_id>
    <secondary_id>CCCWFU-BG03-117</secondary_id>
    <nct_id>NCT00068276</nct_id>
  </id_info>
  <brief_title>Cholecalciferol in Treating Patients With Myelodysplastic Syndrome</brief_title>
  <official_title>Orthomolecular Vitamin D3 in Low-Risk Myelodysplastic Syndrome: An Open-Label Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Cholecalciferol (vitamin D) may improve quality of life by increasing blood&#xD;
      counts, decreasing fatigue, and improving other symptoms of myelodysplastic syndrome.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well cholecalciferol works in treating patients&#xD;
      with myelodysplastic syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the efficacy of cholecalciferol, in terms of hematological improvement, in&#xD;
           patients with low- or intermediate-risk myelodysplastic syndromes.&#xD;
&#xD;
        -  Determine the effect of this drug on disease symptoms, fatigue, and the overall&#xD;
           health-related quality of life of these patients.&#xD;
&#xD;
      OUTLINE: This is an open-label, pilot study.&#xD;
&#xD;
      Patients receive oral cholecalciferol once daily. Treatment continues for 6 months in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 36 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <primary_completion_date type="Actual">June 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Neoplasms</condition>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>cholecalciferol</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed myelodysplastic syndromes (MDS)&#xD;
&#xD;
               -  Must have undergone bone marrow aspirate and biopsy with karyotype within the&#xD;
                  past 3 months&#xD;
&#xD;
          -  International Prognostic Scoring System score of 0 or 1&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Any age&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Any&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 1 year&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  No history of hypercalcemia&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Prior stem cell transplantation allowed&#xD;
&#xD;
          -  No concurrent hematopoietic growth factors&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 6 weeks since prior cholecalciferol supplements or analogs&#xD;
&#xD;
          -  More than 4 weeks since any prior therapy for MDS (except supportive care)&#xD;
&#xD;
          -  No other concurrent therapy for MDS&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Istvan Molnar, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bayard L. Powell, MD</last_name>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Comprehensive Cancer Center at Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1082</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>September 10, 2003</study_first_submitted>
  <study_first_submitted_qc>September 10, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2003</study_first_posted>
  <last_update_submitted>August 8, 2018</last_update_submitted>
  <last_update_submitted_qc>August 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>atypical chronic myeloid leukemia, BCR-ABL1 negative</keyword>
  <keyword>myelodysplastic/myeloproliferative neoplasm, unclassifiable</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

